Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy

References

• Aiello EJ, Buist DS, Wagner EH, . Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat 2008; 107:397–403
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M, . Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365: 60–2
   PubMed Web of Science ®Google Scholar
• Thurlimann B, Keshaviah A, Coates AS, . A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–57
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ, .A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92
   PubMed Web of Science ®Google Scholar
• Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45–53
   PubMed Web of Science ®Google Scholar
• Buzdar A, Howell A, Cuzick J, . Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633–43
   PubMed Web of Science ®Google Scholar
• Khan QJ, O'Dea AP, Sharma P. Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol 2010 Aug 24. Epub ahead of print
   Google Scholar
• Morales L, Neven P, Timmerman D, . Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 2004;15:753–60
   PubMed Web of Science ®Google Scholar
• Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22:4261–71
   PubMed Web of Science ®Google Scholar
• Baumgart J, Nilsson K, Stavreus-Evers A, . Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol 2011;204:26–7
   PubMed Web of Science ®Google Scholar
• Visvanathan K, Gallicchio L, Schilling C, . Cytochrome gene polymorphisms, serum estrogens, and hot flushes in midlife women. Obstet Gynecol 2005;106:1372–81
   PubMed Web of Science ®Google Scholar
• Freeman EW, Sammel MD, Lin H, . Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol 2007;110:230–40
   PubMed Web of Science ®Google Scholar
• Jones SE, Cantrell J, Vukelja S, . Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol 2007;25:4765–71
   PubMed Web of Science ®Google Scholar
• Koeberle D, Thuerlimann B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. Breast Cancer Res Treat 2007;105:55–66
   PubMed Web of Science ®Google Scholar
• Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273–84
   PubMed Web of Science ®Google Scholar
• Ruhstaller T, von Moos R, Rufibach K, . Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology 2009;76:142–8
   PubMed Web of Science ®Google Scholar
• Kirk MC, Hudis CA. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 2008;8:155–61
   PubMed Web of Science ®Google Scholar
• Fontaine C, Meulemans A, Huizing M, . Tolerance of adjuvant letrozole outside of clinical trials. Breast 2008;17: 376–81
   PubMed Web of Science ®Google Scholar
• Helzlsouer KJ, Gallicchio L, MacDonald R, Wood B, Rushovich E. A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein, and musculoskeletal symptoms. Breast Cancer Res Treat 2011 Sept 9. Epub ahead of print
   Web of Science ®Google Scholar
• Whelan TJ, Goss PE, Ingle JN, . Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931–40
   PubMed Web of Science ®Google Scholar
• Antoine C, Vandromme J, Fastrez M, Carly B, Liebens F, Rozenberg S. A survey among breast cancer survivors: treatment of the climacteric after breast cancer. Climacteric 2008;11: 322–8
   PubMed Web of Science ®Google Scholar
• Ohnemus U, Uenalan M, Inzunza J, Gustafsson JA, Paus R. The hair follicle as an estrogen target and source. Endocr Rev 2006;27:677–706
   PubMed Web of Science ®Google Scholar
• Saltiki K, Doukas C, Kanakakis J, Anastasiou E, Mantzou E, Alevizaki M. Severity of cardiovascular disease in women: relation with exposure to endogenous estrogen. Maturitas 2006; 55:51–7
   PubMed Web of Science ®Google Scholar
• Rachon D, Teede H. Ovarian function and obesity – interrelationship, impact on women's reproductive lifespan and treatment options. Mol Cell Endocrinol 2010;316:172–9
   PubMed Web of Science ®Google Scholar
• Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psychooncology 2009;18: 811–21
   PubMed Web of Science ®Google Scholar
• Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol 2008;9:953–61
   PubMed Web of Science ®Google Scholar
• Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008; 107:167–80
   PubMed Web of Science ®Google Scholar
• Stearns V, Isaacs C, Rowland J, .A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11: 17–22
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Kugler JW, Sloan JA, . Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059–63
   PubMed Web of Science ®Google Scholar
• Hershman DL, Shao T, Kushi LH, . Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011;126:529–37
   PubMed Web of Science ®Google Scholar